While the FDA recently stated that GLP-1s are either “available” or have “limited availability,” it has kept them on its drug shortage list. For example, FDA has announced that tirzepatide injections are “currently in shortage,” despite stating that Mounjaro and Zepbound injections are “available.”
Additionally, FDA also announced that semaglutide injections remain “currently in shortage,” with the agency stating that certain Wegovy injections have “limited availability,” while other Wegovy injections, and Ozempic injections, are “available.”
Federal law permits the compounding of copies of FDA-approved drugs when a drug is in shortage. NCPA will keep its members posted on developments.
NCPA
